CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 180 enrolled / 180 target
Drug / intervention
Deucravacitinib +1 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Diagnosed with stable plaque psoriasis for 6 months or more
  • ✓≥3% Body Surface Area (BSA) involvement
  • ✓DLQI score >5
  • ✓Moderate-to-severe plaque psoriasis with static PGA ≥3
Key exclusion· 1
  • ✕Non-plaque psoriasis (guttate, pustular, erythrodermic, palmoplantar only, or drug-induced)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05701995
NCT05701995Phase 4CompletedMonitor (4.4/mo)Completion was 22mo ago
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

Bristol-Myers Squibb·interventional·Posted Jan 27, 2023·Updated Jun 3, 2026

In Brief

A Phase 4 clinical trial evaluating Deucravacitinib and Placebo for Psoriasis. Completed, enrolled 180 participants across 38 sites in 2 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJan 27, 2023
Enrollment StartJan 31, 2023
Primary CompletionAug 23, 2024
Study CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.4 years ago

Arms & Interventions

Deucravacitinibexperimental

Drug: Deucravacitinib
Placebo then Deucravacitinibplacebo_comparator

Drug: DeucravacitinibOther: Placebo

Interventions

Deucravacitinibdrug

Specified dose on specified days.

Placeboother

Specified dose on specified days.